|Table of Contents|

Research progress of neoadjuvant therapy strategies for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 06
Page:
1083-1087
Research Field:
Publishing date:

Info

Title:
Research progress of neoadjuvant therapy strategies for breast cancer
Author(s):
YAN Shuai1; 2; PAN Xixi1; TAO Weiyang1; 2
1.Department of Breast Surgery,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China；2.Department of Breast Surgery,The First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
breast cancer; neoadjuvant therapy; pathological complete response
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2021.06.040
Abstract:
As an essential treatment for breast cancer,neoadjuvant therapy is not limited to locally advanced breast cancer.Pathologic complete response (pCR) is significantly related to the improvement of overall survival (OS) rate and disease-free survival (DFS) rate after neoadjuvant therapy.It is the most objective and efficient evaluation index of neoadjuvant therapy.After neoadjuvant therapy,patients can achieve important diagnosis and treatment purposes such as tumor downgrading,improving breast preservation rate,and sufficient observation of tumor drug sensitivity.Accurate efficacy analysis can help clinicians switch their diagnosis and treatment strategies in time,provide patients with individualized treatment plans,and avoid undertreatment or overtreatment.This article reviews the latest research progress on the problems of anthracycline removal in neoadjuvant chemotherapy,neoadjuvant targeted therapy for HER2-positive breast cancer,neoadjuvant immunotherapy for triple-negative breast cancer,the timing of surgery and choice of surgical methods.

References:

［1］ HARBECK N,GNANT M.Breast cancer［J］.Lancet,2017,389(10074):1134-1150.
［2］ BALIC M,THOMSSEN C,WURSTLEIN R,et al.St.Gallen/Vienna 2019:A brief summary of the consensus discussion on the optimal primary breast cancer treatment［J］.Breast Care (Basel),2019,14(2):103-110.
［3］ LIEDTKE C,JACKISCH C,THILL M,et al.AGO recommendations for the diagnosis and treatment of patients with early breast cancer:Update 2018［J］.Breast Care (Basel),2018,13(3):196-208.
［4］ Early Breast Cancer Trialists' Collaborative Group (EBCTCG),PETO R,DAVIES C,et al.Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of long-term outcome among 100,000 women in 123 randomised trials［J］.Lancet,2012,379(9814):432-444.
［5］ SMITH LA,CORNELIUS VR,PLUMMER CJ,et al.Cardiotoxicity of anthracycline agents for the treatment of cancer:systematic review and meta-analysis of randomised controlled trials［J］.BMC Cancer,2010,29(10):337-337.
［6］ EWER MS,LIPPMAN SM.Type II chemotherapy-related cardiac dysfunction:time to recognize a new entity［J］.J Clin Oncol,2005,23(13):2900-2902.
［7］ SCHNEEWEISS A,CHIA S,HICKISH T,et al.Long-term efficacy analysis of the randomised,phase II TRYPHAENA cardiac safety study:Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer［J］.Eur J Cancer,2018,89:27-35.
［8］ GUENANCIA C,LEFEBVRE A,CARDINALE D,et al.Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer:A systematic review and Meta-analysis［J］.J Clin Oncol,2016,34(26):3157-3165.
［9］ KOTWINSKI P,SMITH G,COOPER J,et al.Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer［J］.PLoS One,2016,11(12):e0165262-e0165262.
［10］ VAN RAMSHORST MS,VAN DER VOORT A,VAN WERKHOVEN ED,et al.Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2):a multicentre,open-label,randomised,phase 3 trial［J］.Lancet Oncol,2018,19(12):1630-1640.
［11］ TANAKA S,MATSUNAMI N,MORISHIMA H,et al.De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer［J］.Cancer Chemother Pharmacol,2019,83(6):1099-1104.
［12］ NONE.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer［J］.N Engl J Med,2015,373(20):1989.
［13］ PICCART M,PROCTER M,FUMAGALLI D,et al.Interim overall survival analysis of APHINITY (BIG 4-11):a randomized multicenter,double-blind,placebo-controlled［J］.Cancer Res,2020,80(01):abstr01-04.
［14］ SCHNEEWEISS A,CHIA S,HICKISH T,et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:a randomized phase II cardiac safety study (TRYPHAENA)［J］.Ann Oncol,2013,24(9):2278-2284.
［15］ GIANNI L,PIENKOWSKI T,IM YH,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer (NeoSphere):a randomised multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2012,13(1):25-32.
［16］ YU AF,SINGH JC,WANG R,et al.Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer［J］.Oncologist,2017,22(6):642-647.
［17］ VAN RAMSHORST MS,VAN WERKHOVEN E,HONKOOP AH,et al.Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer:The TRAIN-2 study［J］.Breast,2016,29:153-159.
［18］ NITZ UA,GLUZ O,CHRISTGEN M,et al.De-escalation strategies in HER2-positive early breast cancer (EBC):final analysis of the WSG-ADAPT HER2+/HR- phase II trial:efficacy,safety,and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab±weekly paclitaxel［J］.Ann Oncol,2017,28(11):2768-2772.
［19］ GIANNI L,BISAGNI G,COLLEONI M,et al.Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive,ER-positive breast cancer (NA-PHER2):an exploratory,open-label,phase 2 study［J］.Lancet Oncol,2018,19(2):249-256.
［20］ GUARNERI V,DIECI MV,BISAGNI G,et al.De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole:results of the PerELISA neoadjuvant study［J］.Ann Oncol,2019,30(6):921-926.
［21］ CORTAZAR P,ZHANG L,UNTCH M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis［J］.Lancet,2014,384(9938):164-172.
［22］ NONE.Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer［J］.N Engl J Med,2017,377(7):702.
［23］ VON MINCKWITZ G,HUANG CS,MANO MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］.N Engl J Med,2019,380(7):617-628.
［24］ CHAN A,DELALOGE S,HOLMES FA,et al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET):a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2016,17(3):367-377.
［25］ PATHAK M,DWIVEDI SN,DEO S,et al.Effectiveness of added targeted therapies to neoadjuvant chemotherapy for breast cancer:A systematic review and Meta-analysis［J］.Clin Breast Cancer,2019,19(6):e690-e700.
［26］ WANG BC,FU C,XIE LK,et al.Comparative toxicities of neoadjuvant chemotherapy with or without bevacizumab in HER2-negative breast cancer patients:A Meta-analysis［J］.Ann Pharmacother,2020,54(6):517-525.
［27］ SCHMID P,CORTES J,PUSZTAI L,et al.Pembrolizumab for early triple-negative breast cancer［J］.N Engl J Med,2020,382(9):810-821.
［28］ GIANNI L,CS H,EGLE D,et al.Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative,early high-riskand locally advanced breast cancer.NeoTRIPaPDL1 Michelangelo randomized study［J］.Cancer Res,2020,80(01):abstr03-04.
［29］ SELIGER B.231PImmunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89,Geparnuevo trial)［J］.Ann Oncol,2018,29(1):suppl8.
［30］ BEAR HD,WAN W,ROBIDOUX A,et al.Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer:A multicenter trial［J］.J Surg Oncol,2017,115(8):917-923.
［31］ SAVARIDAS SL,SIM YT,VINNICOMBE SJ,et al.Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer［J］.Cancer Imaging,2019,19(1):67.
［32］ KRIZMANICH-CONNIFF KM,PARAMAGUL C,PATTERSON SK,et al.Triple receptor-negative breast cancer:imaging and clinical characteristics［J］.AJR Am J Roentgenol,2012,199(2):458-464.
［33］ VAN LA PARRA R,TADROS AB,CHECKA CM,et al.Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer［J］.Br J Surg,2018,105(5):535-543.
［34］ SCHEEL JR,KIM E,PARTRIDGE SC,et al.MRI,clinical examination,and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer:ACRIN 6657 trial［J］.AJR Am J Roentgenol,2018,210(6):1376-1385.
［35］ BASIK M,COSTANTINO J,DE LOS SANTOS J,et al.Phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic response in patients with clinical/radiological complete response after neoadjuvant chemotherapy in order to explore the feasibility of breast-conserving surgery without surgery:NRG Oncology［J］.Cancer Res,2019,79(1):abstrOT10901.
［36］ HEIL J,PFOB A,H-PP S,et al.Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by［J］.Cancer Res,2020,80(1):abstr05-03.
［37］ BLEICHER RJ.Timing and delays in breast cancer evaluation and treatment［J］.Ann Surg Oncol,2018,25(10):2829-2838.
［38］ ZHAN QH,FU JQ,FU FM,et al.Survival and time to initiation of adjuvant chemotherapy among breast cancer patients:a systematic review and meta-analysis［J］.Oncotarget,2018,9(2):2739-2751.
［39］ SULEMAN K,ALMALIK O,HAQUE E,et al.Does the timing of surgery after neoadjuvant therapy in breast cancer patients affect the outcome［J］.Oncology,2020,98(3):168-173.
［40］ WHITE RL JR,PALMER PP,TRUFAN SJ,et al.Does neoadjuvant chemotherapy for breast cancer affect lymph node harvest rates［J］.Am Surg,2019,85(7):690-694.
［41］ ROSENBERGER LH,REN Y,THOMAS SM,et al.Axillary lymph node dissection in node-positive breast cancer:are ten nodes adequate and when is enough,enough［J］.Breast Cancer Res Treat,2019,179(3):661-670.
［42］ ERBES T,ORLOWSKA-VOLK M,ZUR HAUSEN A,et al.Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection［J］.BMC Cancer,2014,03(14):4.
［43］ NGUYEN TT,HOSKIN TL,DAY CN,et al.Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy［J］.Ann Surg Oncol,2018,25(9):2596-2602.
［44］ VON MINCKWITZ G,UNTCH M,BLOHMER JU,et al.Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］.J Clin Oncol,2012,30(15):1796-1804.
［45］ CAUDLE AS,YANG WT,KRISHNAMURTHY S,et al.Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes:Implementation of targeted axillary dissection［J］.J Clin Oncol,2016,34(10):1072-1078.
［46］ GIULIANO AE,BALLMAN KV,MCCALL L,et al.Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis:The ACOSOG Z0011 (alliance) randomized clinical trial［J］.JAMA,2017,318(10):918-926.
［47］ CHOI J,LAWS A,HU J,et al.Margins in breast-conserving surgery after neoadjuvant therapy［J］.Ann Surg Oncol,2018,25(12):3541-3547.
［48］ LIN J,LIN KJ,WANG YF,et al.Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy［J］.BMC Cancer,2020,20(1):451.

Memo

Memo:
黑龙江省自然科学基金面上项目（编号：H2016052）；黑龙江省博士后科研启动金（编号：LBH-Q17100）
Last Update: 1900-01-01